BR0207267A - Proteìnas artificiais com imunogenicidade reduzida - Google Patents
Proteìnas artificiais com imunogenicidade reduzidaInfo
- Publication number
- BR0207267A BR0207267A BR0207267-0A BR0207267A BR0207267A BR 0207267 A BR0207267 A BR 0207267A BR 0207267 A BR0207267 A BR 0207267A BR 0207267 A BR0207267 A BR 0207267A
- Authority
- BR
- Brazil
- Prior art keywords
- fusion proteins
- relates
- molecule
- molecules
- reduced immunogenicity
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 title abstract 4
- 230000005847 immunogenicity Effects 0.000 title abstract 3
- 102000037865 fusion proteins Human genes 0.000 abstract 4
- 108020001507 fusion proteins Proteins 0.000 abstract 4
- 108060003951 Immunoglobulin Proteins 0.000 abstract 3
- 102000018358 immunoglobulin Human genes 0.000 abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000043131 MHC class II family Human genes 0.000 abstract 1
- 108091054438 MHC class II family Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 230000008105 immune reaction Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
"PROTEìNAS ARTIFICIAIS COM IMUNOGENICIDADE REDUZIDA". A invenção refere-se às proteínas artificiais modificadas, preferivelmente as proteínas de fusão, tendo uma imunogenicidade reduzida em comparação com a molécula não-modificada de origem quando expostas a uma espécie in vivo. A invenção refere-se, acima de tudo, às novas proteínas de fusão de imunoglobulina, as quais essencialmente consistem em uma molécula de imunoglobulina, ou um fragmento da mesma, covalentemente fundida por meio de sua extremidade de C à extremidade de N de uma molécula que não é de imunoglobulina biologicamente ativa, preferivelmente um polipeptídeo ou proteína ou um seu fragmento biologicamente ativo. Em uma modalidade específica, a invenção refere-se às proteínas de fusão consistindo em uma porção Fc de um anticorpo que está fundido, como mencionado, à molécula-alvo não-imunológica, o que faz surgir eficácia biológica ou farmacológica. As moléculas da invenção têm seq³ências de aminoácidos que são alteradas em uma ou mais posições de resíduos de aminoácidos, porém têm, no básico, a mesma atividade biológica em comparação com as moléculas não-alteradas. As mudanças são feitas em regiões das moléculas que são identificadas como epítopos de células T, que contribuem para uma reação imune em um hospedeiro vivo. Assim, a invenção também refere-se a um novo método para a preparação de tais proteínas de fusão por identificação dos ditos epítopos, compreendendo o cálculo dos valores de epítopos de células T para os locais de ligação às moléculas de MHC da Classe II em um peptídeo por métodos auxiliados por computador.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01103955 | 2001-02-19 | ||
EP01108291 | 2001-04-05 | ||
PCT/EP2002/001690 WO2002066514A2 (en) | 2001-02-19 | 2002-02-18 | Artificial fusion proteins with reduced immunogenicity |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0207267A true BR0207267A (pt) | 2004-02-10 |
Family
ID=26076484
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0207267-0A BR0207267A (pt) | 2001-02-19 | 2002-02-18 | Proteìnas artificiais com imunogenicidade reduzida |
Country Status (13)
Country | Link |
---|---|
US (2) | US7189830B2 (pt) |
EP (1) | EP1361891A2 (pt) |
JP (1) | JP2004532620A (pt) |
KR (1) | KR20040074587A (pt) |
CN (1) | CN100522242C (pt) |
AU (1) | AU2002233340B2 (pt) |
BR (1) | BR0207267A (pt) |
CA (1) | CA2438628A1 (pt) |
HU (1) | HUP0303171A2 (pt) |
MX (1) | MXPA03007323A (pt) |
PL (1) | PL362324A1 (pt) |
RU (1) | RU2363707C2 (pt) |
WO (1) | WO2002066514A2 (pt) |
Families Citing this family (130)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2312188C (en) | 1997-12-08 | 2010-06-29 | Lexigen Pharmaceuticals Corp. | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
US20030105294A1 (en) * | 1998-02-25 | 2003-06-05 | Stephen Gillies | Enhancing the circulating half life of antibody-based fusion proteins |
BR9909583A (pt) * | 1998-04-15 | 2002-01-15 | Lexigen Pharm Corp | Aumento da resposta imune mediado por uma proteìna de fusão anticorpo-citocina por co-administração com inibidor de angiogênese |
US6548653B1 (en) * | 1998-06-15 | 2003-04-15 | Genzyme Transgenics Corporation | Erythropoietin analog-human serum albumin fusion |
SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
US6617135B1 (en) * | 1999-08-09 | 2003-09-09 | Emd Lexigen Research Center Corp. | Multiple cytokine protein complexes |
US20050202538A1 (en) * | 1999-11-12 | 2005-09-15 | Merck Patent Gmbh | Fc-erythropoietin fusion protein with improved pharmacokinetics |
DK1252192T3 (da) * | 2000-02-11 | 2006-11-20 | Merck Patent Gmbh | Forbedring af antistofbaserede fusionsproteiners serumhalveringstid |
BR0112111A (pt) * | 2000-06-29 | 2003-05-06 | Merck Patent Gmbh | Realce de respostas imunes mediadas por proteìna de fusão de anticorpo-citocina por tratamento combinado com agentes de realce de captação de imunocitocina |
MXPA03008031A (es) * | 2001-03-07 | 2003-12-04 | Merck Patent Gmbh | Tecnologia de expresion para proteinas que contienen porcion de anticuerpo isotipo hibrida. |
WO2002079415A2 (en) * | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
DK1383785T3 (da) * | 2001-05-03 | 2011-05-23 | Merck Patent Gmbh | Rekombinant tumorspecifikt antistof og anvendelse deraf |
US20060073141A1 (en) * | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
US20050271663A1 (en) * | 2001-06-28 | 2005-12-08 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
AU2002357784B2 (en) | 2001-12-04 | 2008-07-31 | Merck Patent Gmbh | Immunocytokines with modulated selectivity |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
US7611700B2 (en) * | 2002-09-09 | 2009-11-03 | Hanall Pharmaceuticals, Co., Ltd. | Protease resistant modified interferon alpha polypeptides |
JP4494977B2 (ja) * | 2002-12-17 | 2010-06-30 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Gd2に結合するマウス14.18抗体のヒト化抗体(h14.18)およびそのil−2融合タンパク質 |
US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
ES2327409T3 (es) | 2003-03-26 | 2009-10-29 | Apogenix Gmbh | Proteinas de fusion fc mejoradas. |
US9051373B2 (en) | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
US8147832B2 (en) * | 2003-08-14 | 2012-04-03 | Merck Patent Gmbh | CD20-binding polypeptide compositions and methods |
CA2536408A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
US20050069521A1 (en) * | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
US9714282B2 (en) | 2003-09-26 | 2017-07-25 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
EP1673398B1 (en) | 2003-10-16 | 2010-12-29 | Micromet AG | Multispecific deimmunized cd3-binders |
US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
KR20050047030A (ko) | 2003-11-13 | 2005-05-19 | 한미약품 주식회사 | 약물의 캐리어로서 유용한 IgG Fc 단편 및 그의제조방법 |
BRPI0418286A (pt) | 2003-12-30 | 2007-05-02 | Merck Patent Gmbh | proteìnas de fusão de il-7 |
KR20060124656A (ko) * | 2003-12-31 | 2006-12-05 | 메르크 파텐트 게엠베하 | 개선된 약물동태를 가지는 Fc-에리스로포이에틴 융합단백질 |
AU2005203962C1 (en) | 2004-01-05 | 2012-11-08 | Antisoma Research Limited | Interleukin-12 targeted to oncofoetal fibronectin |
EP1706428B1 (en) | 2004-01-22 | 2009-09-23 | MERCK PATENT GmbH | Anti-cancer antibodies with reduced complement fixation |
US7674464B2 (en) * | 2004-03-04 | 2010-03-09 | The University Of Tennessee Research Foundation | Intracellular interleukin-1 receptor antagonists |
US7670595B2 (en) * | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
US20150010550A1 (en) | 2004-07-15 | 2015-01-08 | Xencor, Inc. | OPTIMIZED Fc VARIANTS |
US7470521B2 (en) * | 2004-07-20 | 2008-12-30 | Critical Therapeutics, Inc. | RAGE protein derivatives |
US8647625B2 (en) | 2004-07-26 | 2014-02-11 | Biogen Idec Ma Inc. | Anti-CD154 antibodies |
US20090060925A1 (en) * | 2004-08-03 | 2009-03-05 | The Trustees Of Columbia University In The City Of | Rage Fusion Proteins and Methods of Use |
EP1781700B1 (en) | 2004-08-03 | 2014-03-19 | TransTech Pharma, LLC | Rage fusion proteins and methods of use |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
EP2325207B1 (en) | 2004-11-12 | 2017-03-15 | Xencor, Inc. | FC variants with altered binding to FCRN |
KR20070085886A (ko) * | 2004-12-09 | 2007-08-27 | 메르크 파텐트 게엠베하 | 감소된 면역원성의 il-7 변이체 |
US20060275282A1 (en) * | 2005-01-12 | 2006-12-07 | Xencor, Inc. | Antibodies and Fc fusion proteins with altered immunogenicity |
CA2597584A1 (en) * | 2005-02-15 | 2006-08-24 | Apollo Life Sciences Limited | Molecules and chimeric molecules thereof |
US7833979B2 (en) * | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
US20070104689A1 (en) * | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
WO2007041317A2 (en) * | 2005-09-29 | 2007-04-12 | Viral Logic Systems Technology Corp. | Immunomodulatory compositions and uses therefor |
ES2856451T3 (es) | 2005-10-11 | 2021-09-27 | Amgen Res Munich Gmbh | Composiciones que comprenden anticuerpos específicos para diferentes especies, y usos de las mismas |
CN101360759A (zh) | 2005-11-07 | 2009-02-04 | 哥本哈根大学 | 神经营养因子衍生的肽序列 |
ES2595091T3 (es) | 2005-12-21 | 2016-12-27 | Amgen Research (Munich) Gmbh | Composiciones farmacéuticas con resistencia a CEA soluble |
BRPI0620380B1 (pt) * | 2005-12-23 | 2018-04-24 | Gcoder Systems Ab | Padrão de posicionamento |
ATE555125T1 (de) * | 2005-12-30 | 2012-05-15 | Merck Patent Gmbh | Interleukin-12p40-varianten mit verbesserter stabilität |
JP2009521912A (ja) | 2005-12-30 | 2009-06-11 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 低減された免疫原性を有する抗cd19抗体 |
NZ569545A (en) * | 2006-02-09 | 2011-11-25 | Transtech Pharma Inc | Rage fusion proteins and methods of use for treating inflammation |
US8293500B2 (en) | 2006-03-22 | 2012-10-23 | Viral Logic Systems Technology Corp. | Methods for identifying polypeptide targets and uses thereof for treating immunological diseases |
WO2007113285A2 (en) * | 2006-03-31 | 2007-10-11 | Biotherapix Molecular Medicines S.L.U. | Mono- and bifunctional molecules with ability to bind to g protein-coupled receptors |
CN100402551C (zh) * | 2006-04-14 | 2008-07-16 | 中国科学院长春应用化学研究所 | β2-微球蛋白的抗原表位及应用 |
WO2007130302A2 (en) * | 2006-05-05 | 2007-11-15 | Transtech Pharma, Inc. | Rage fusion proteins, formulations, and methods of use thereof |
US8377448B2 (en) * | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
JP2009537145A (ja) * | 2006-05-15 | 2009-10-29 | バイラル ロジック システムズ テクノロジー コーポレーション | 免疫学的疾患および障害を治療するためのcd47と関連した組成物および方法 |
WO2008045380A2 (en) * | 2006-10-04 | 2008-04-17 | Codon Devices, Inc. | Nucleic acid libraries and their design and assembly |
EP2120998B1 (en) | 2006-11-28 | 2013-08-07 | HanAll Biopharma Co., Ltd. | Modified erythropoietin polypeptides and uses thereof for treatment |
JP2008169195A (ja) | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
WO2008100470A2 (en) * | 2007-02-15 | 2008-08-21 | Transtech Pharma, Inc. | Rage - immunoglobulin fusion proteins |
WO2008149147A2 (en) * | 2007-06-06 | 2008-12-11 | Domantis Limited | Polypeptides, antibody variable domains and antagonists |
WO2009014835A2 (en) * | 2007-06-21 | 2009-01-29 | Angelica Therapeutics, Inc. | Modified toxins |
JP6035009B2 (ja) | 2007-08-22 | 2016-11-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用 |
GB0723712D0 (en) * | 2007-12-04 | 2008-01-16 | Apitope Technology Bristol Ltd | Peptides |
HUE024903T2 (en) | 2007-12-26 | 2016-02-29 | Xencor Inc | FC variants with modified binding to FCRN |
EP2769991B1 (en) * | 2008-01-03 | 2018-08-22 | The Scripps Research Institute | Antibody targeting through a modular recognition domain |
WO2009110944A1 (en) * | 2008-02-29 | 2009-09-11 | Angelica Therapeutics, Inc. | Modified toxins |
US20110160071A1 (en) * | 2008-06-03 | 2011-06-30 | Baynes Brian M | Novel Proteins and Methods for Designing the Same |
US8734795B2 (en) | 2008-10-31 | 2014-05-27 | Biogen Idec Ma Inc. | Light targeting molecules and uses thereof |
JP5851842B2 (ja) | 2009-01-12 | 2016-02-03 | サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. | 改変した抗体組成物、それを作製および使用する方法 |
WO2010096838A2 (en) | 2009-02-23 | 2010-08-26 | Cytomx Therapeutics, Llc | Proproteins and methods of use thereof |
CN101863982A (zh) * | 2009-04-17 | 2010-10-20 | 哈药集团生物工程有限公司 | 一种用于升高血小板的融合蛋白及其制备方法 |
EP2421892A1 (en) | 2009-04-20 | 2012-02-29 | Pfizer Inc. | Control of protein glycosylation and compositions and methods relating thereto |
AU2010238858A1 (en) | 2009-04-22 | 2011-12-08 | Merck Patent Gmbh | Antibody fusion proteins with modified FcRn binding sites |
WO2011002673A1 (en) * | 2009-07-01 | 2011-01-06 | Temple University - Of The Commonwealth System Of Higher Education | Leptin agonist and methods of use |
EP3636759B1 (en) | 2009-07-17 | 2023-10-11 | BioAtla, Inc. | Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts |
WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
US8362210B2 (en) | 2010-01-19 | 2013-01-29 | Xencor, Inc. | Antibody variants with enhanced complement activity |
WO2011098095A1 (en) * | 2010-02-09 | 2011-08-18 | Aplagen Gmbh | Peptides binding the tpo receptor |
JP5840148B2 (ja) | 2010-03-04 | 2016-01-06 | フェニックス インク. | 変性させることなく可溶性組換えインターフェロンタンパク質を産生する方法 |
EP2552949B1 (en) | 2010-04-01 | 2016-08-17 | Pfenex Inc. | Methods for g-csf production in a pseudomonas host cell |
ES2826445T3 (es) * | 2010-04-28 | 2021-05-18 | Oncolmmune Inc | Uso médico de CD24 soluble |
US20120100166A1 (en) | 2010-07-15 | 2012-04-26 | Zyngenia, Inc. | Ang-2 Binding Complexes and Uses Thereof |
SG10201902596TA (en) | 2010-07-16 | 2019-04-29 | Bioatla Llc | Novel methods of protein evolution |
CA2823044C (en) | 2010-12-31 | 2022-08-16 | Jay M. Short | Express humanization of antibodies |
AU2011352207B2 (en) | 2010-12-31 | 2016-03-03 | Bioatla, Llc | Comprehensive monoclonal antibody generation |
JP5979673B2 (ja) * | 2011-02-18 | 2016-08-24 | 国立大学法人京都大学 | タンパク質水溶液 |
WO2012119989A2 (en) | 2011-03-04 | 2012-09-13 | Oryzon Genomics, S.A. | Methods and antibodies for the diagnosis and treatment of cancer |
ES2704038T3 (es) | 2011-05-24 | 2019-03-13 | Zyngenia Inc | Complejos multiespecíficos multivalentes y monovalentes y sus usos |
KR20140100543A (ko) | 2011-11-29 | 2014-08-14 | 뉴로페이지 파마슈티컬즈, 인크. | 박테리오파아지 유전자 3 단백질 조성물 및 아밀로이드 결합제로서의 용도 |
US9969813B2 (en) | 2012-05-10 | 2018-05-15 | Bioatla, Llc | Multi-specific monoclonal antibodies |
ES2641373T3 (es) | 2012-10-02 | 2017-11-08 | Proclara Biosciences, Inc. | Uso de P3 de proteínas de fusión de bacteriófagos como agentes de unión amiloides |
WO2014150600A2 (en) | 2013-03-15 | 2014-09-25 | Angelica Therapeutics, Inc. | Modified toxins |
BR112015023752B1 (pt) | 2013-03-15 | 2023-11-14 | Zyngenia, Inc. | Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo |
EP3003349B1 (en) | 2013-05-28 | 2018-12-12 | Proclara Biosciences, Inc. | Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity |
NZ715455A (en) | 2013-07-09 | 2021-12-24 | Annexon Inc | Anti-complement factor c1q antibodies and uses thereof |
EP2840091A1 (en) * | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof |
EP3447493B1 (en) | 2014-01-07 | 2020-05-13 | Bioatla, LLC | Proteins targeting orthologs |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
KR20160131073A (ko) | 2014-03-12 | 2016-11-15 | 프로테나 바이오사이언시즈 리미티드 | Lg4-5에 대해 특이적인 항-라미닌4 항체 |
US20170002077A1 (en) * | 2014-03-13 | 2017-01-05 | Prothena Biosciences Limited | Combination treatment for multiple sclerosis |
KR20150140177A (ko) * | 2014-06-05 | 2015-12-15 | 한미약품 주식회사 | 단백질 및 펩타이드의 면역원성을 감소시키는 방법 |
BR112017009297B1 (pt) * | 2014-11-05 | 2024-02-15 | Annexon, Inc | Anticorpos antifator de complemento c1q humanizados, composição farmacêutica e kit compreendendo os mesmos, uso terapêutico destes,polinucleotídeo isolado, célula hospedeira isolada, bem como métodos in vitro para detectar sinapses |
WO2016087514A1 (en) | 2014-12-02 | 2016-06-09 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies |
AU2015358504A1 (en) | 2014-12-03 | 2017-06-29 | Proclara Biosciences, Inc. | Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a glycosylation signal |
JP6907199B2 (ja) * | 2015-10-30 | 2021-07-21 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | D−タンパク質リガンドの構造ベース設計 |
GB201520568D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd | Peptides |
GB201520550D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
GB201520545D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
CN115260310A (zh) | 2015-11-24 | 2022-11-01 | 安尼艾克松股份有限公司 | 抗补体因子c1q的fab片段及其应用 |
GB201607521D0 (en) * | 2016-04-29 | 2016-06-15 | Oncolmmunity As | Method |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
US20200123198A1 (en) * | 2016-10-04 | 2020-04-23 | The Council Of The Queensland Institute Of Medical Research (Qimr) | Peptide Libraries and Methods of Use |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
JP6925431B2 (ja) * | 2016-11-09 | 2021-08-25 | フィロジェン エッセ.ピー.アー. | Il2及びtnf突然変異体のイムノコンジュゲート |
CN110913881A (zh) * | 2017-03-14 | 2020-03-24 | 加利福尼亚大学董事会 | 工程化crispr cas9免疫隐身 |
WO2019014650A1 (en) * | 2017-07-13 | 2019-01-17 | City Of Hope | ANTICANCER CONJUGATES OF PEPTIDE COUPLED WITH PHOSPHOROTHIOATE AND METHODS OF USE THEREOF |
US11541121B2 (en) | 2017-07-13 | 2023-01-03 | City Of Hope | Phosphorothioate-conjugated peptides and methods of using the same |
CA3086199A1 (en) | 2017-12-19 | 2019-06-27 | Xencor, Inc. | Engineered il-2 fc fusion proteins |
JP2022503959A (ja) | 2018-10-03 | 2022-01-12 | ゼンコア インコーポレイテッド | Il-12ヘテロ二量体fc-融合タンパク質 |
AU2020358979A1 (en) | 2019-10-03 | 2022-04-21 | Xencor, Inc. | Targeted IL-12 heterodimeric Fc-fusion proteins |
CN112457399B (zh) * | 2020-12-19 | 2023-09-01 | 上海佰君生物科技有限公司 | 一种人免疫球蛋白g的提纯方法 |
CN112466390B (zh) * | 2020-12-19 | 2023-11-14 | 广东众源药业有限公司 | 可用于纯化人免疫球蛋白g的疏水性环状肽配基 |
CN115724988B (zh) * | 2021-08-26 | 2023-11-17 | 瑅安生物医药(杭州)有限公司 | 一种接近天然分子的多肽融合分子 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5650150A (en) * | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
GB9511935D0 (en) * | 1995-06-13 | 1995-08-09 | Smithkline Beecham Plc | Novel compound |
EP0983303B1 (en) * | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
DE19822406A1 (de) | 1998-05-19 | 1999-11-25 | Alexander Cherkasky | Therapeutisches Präparat: Monoklonale Immunogenische Protease (MIP)/Monoklonales Immunogenisches Chymotrypsin (MIC) |
ATE352559T1 (de) * | 1998-12-08 | 2007-02-15 | Biovation Ltd | Verfahren zur verminderung der immunogenität von proteinen |
BR0007414A (pt) * | 1999-01-07 | 2001-10-16 | Lexigen Pharm Corp | Expressão e exportação de proteìnas antiobesidade como proteìnas de fusão fc |
DE19925052B4 (de) | 1999-06-01 | 2012-01-12 | Alexander Cherkasky | Proteinkomplexe für den zielgerichteten Transport von (Poly)Peptide und Nukleinsäuren und sequenzspezifische Integration von DNA-Vektoren |
HUP0303173A2 (hu) * | 2001-02-19 | 2003-12-29 | Merck Patent Gmbh | Csökkent immunogenitású, módosított anti-EGFR-ellenanyagok |
DE10133071A1 (de) | 2001-07-07 | 2003-03-06 | Alexander Cherkasky | Antigene, Rezeptoren, Liganden oder ihre Regionen kombiniert mit proteolytischer Aktivität |
-
2002
- 2002-02-18 MX MXPA03007323A patent/MXPA03007323A/es not_active Application Discontinuation
- 2002-02-18 US US10/468,370 patent/US7189830B2/en not_active Expired - Fee Related
- 2002-02-18 PL PL36232402A patent/PL362324A1/xx not_active Application Discontinuation
- 2002-02-18 WO PCT/EP2002/001690 patent/WO2002066514A2/en active Application Filing
- 2002-02-18 CN CNB028051580A patent/CN100522242C/zh not_active Expired - Fee Related
- 2002-02-18 RU RU2003127387/13A patent/RU2363707C2/ru not_active IP Right Cessation
- 2002-02-18 JP JP2002566227A patent/JP2004532620A/ja active Pending
- 2002-02-18 HU HU0303171A patent/HUP0303171A2/hu unknown
- 2002-02-18 EP EP02700246A patent/EP1361891A2/en not_active Withdrawn
- 2002-02-18 CA CA002438628A patent/CA2438628A1/en not_active Abandoned
- 2002-02-18 BR BR0207267-0A patent/BR0207267A/pt not_active IP Right Cessation
- 2002-02-18 AU AU2002233340A patent/AU2002233340B2/en not_active Ceased
- 2002-02-18 KR KR10-2003-7010884A patent/KR20040074587A/ko not_active Application Discontinuation
-
2007
- 2007-03-12 US US11/716,878 patent/US7615217B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2002066514A3 (en) | 2003-02-13 |
RU2363707C2 (ru) | 2009-08-10 |
US7189830B2 (en) | 2007-03-13 |
AU2002233340B2 (en) | 2008-05-22 |
KR20040074587A (ko) | 2004-08-25 |
MXPA03007323A (es) | 2003-12-12 |
EP1361891A2 (en) | 2003-11-19 |
US20040082039A1 (en) | 2004-04-29 |
JP2004532620A (ja) | 2004-10-28 |
CN1492768A (zh) | 2004-04-28 |
CA2438628A1 (en) | 2002-08-29 |
CN100522242C (zh) | 2009-08-05 |
US20070269435A1 (en) | 2007-11-22 |
WO2002066514A2 (en) | 2002-08-29 |
HUP0303171A2 (hu) | 2003-12-29 |
US7615217B2 (en) | 2009-11-10 |
RU2003127387A (ru) | 2005-03-27 |
PL362324A1 (en) | 2004-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0207267A (pt) | Proteìnas artificiais com imunogenicidade reduzida | |
Südhof et al. | Cassette of eight exons shared by genes for LDL receptor and EGF precursor | |
Rosenberg | Protein analysis and purification: benchtop techniques | |
CN108289941B (zh) | 用于消除对治疗剂的免疫应答的改进的方法和化合物 | |
Morris et al. | Isolation and characterization of human calcitonin gene-related peptide | |
Smithies et al. | Dog homologue of human β2-microglobulin | |
Hirano et al. | Design and synthesis of a homogeneous erythropoietin analogue with two human complex‐type sialyloligosaccharides: combined use of chemical and bacterial protein expression methods | |
Haniu et al. | Human Leptin Receptor: DETERMINATION OF DISULFIDE STRUCTURE ANDN-GLYCOSYLATION SITES OF THE EXTRACELLULAR DOMAIN | |
NO975435L (no) | Modifiserte/kimeriske proteiner samt anvendelse derav | |
Macmillan et al. | Solid-phase synthesis of thioether-linked glycopeptide mimics for application to glycoprotein semisynthesis | |
Keller et al. | Abalone (Haliotis tuberculata) hemocyanin type 1 (HtH1) Organization of the≈ 400 kDa subunit, and amino acid sequence of its functional units f, g and h | |
Lanzillotti et al. | The 10 kDa domain of human erythrocyte protein 4.1 binds the Plasmodium falciparum EBA-181 protein | |
US5989554A (en) | High level expression and facile purification of proteins, peptides and conjugates for immunization, purification and detection applications | |
Luo et al. | Residues 48 and 82 at the N-terminal hydrophobic pocket of rabbit skeletal muscle troponin-C photo-cross-link to Met121 of troponin-I | |
Zal et al. | Investigation by electrospray ionization mass spectrometry of the extracellular hemoglobin from the polychaete annelid Alvinella pompejana: an unusual hexagonal bilayer hemoglobin | |
JP2004520836A (ja) | 低減された免疫原性を有する修飾されたプロタミン | |
Barron-Casella et al. | Expression and Purification of Functional Recombinant Epitopes for the Platelet Antigens, PIA1 and PIA2 | |
US20060217302A1 (en) | Paralytic peptide for use in neuromuscular therapy | |
US6764689B1 (en) | High level expression and facile purification of proteins, peptides and conjugates for immunization, purification and detection applications | |
JP2803184B2 (ja) | 酸性線維芽細胞成長因子の抗体,その用途およびペプチド | |
Robinson et al. | Characterization of a novel glycoprotein isolated from the basement membrane matrix of the Engelbreth-Holm-Swarm tumor | |
Galat et al. | Subunit of glycosylation-inhibiting factor is an abundant protein that binds to certain glycoproteins and sugars | |
Rosenberg | Protein Analysis | |
ES2351685T3 (es) | Proteína similar a la proteína específica neuroendocrina y adnc codificante. | |
Dellaratta et al. | Characterization of rabbit antisera elicited with human LMP2‐and LMP7‐specific peptides and recombinant proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE(S). |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2103 DE 26/04/2011. |